A low-temperature-resistant synergistic biological agent, a preparation method and application thereof

By combining genetically engineered Bacillus subtilis with PDRN and biostimulants in a ternary compound, the limitations of existing low-temperature resistance technologies have been overcome, enabling crop growth promotion and soil improvement under low-temperature conditions, thereby enhancing crop low-temperature tolerance and yield.

CN122271331APending Publication Date: 2026-06-26SINOCHEM AGRI LINYI R&D CENT CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SINOCHEM AGRI LINYI R&D CENT CO LTD
Filing Date
2026-03-13
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

Existing methods for combating low temperatures are costly, have a narrow range of applications, leave chemical residues, and have limited effectiveness with single microbial agents. They are insufficient to address the problems of slow crop cell repair, insufficient energy supply, and rhizosphere microecological imbalance under low temperatures.

Method used

By combining genetically engineered Bacillus subtilis with polydeoxyribonucleic acid (PDRN) and various biostimulants in a ternary complex, a synergistic low-temperature resistance mechanism is formed. This mechanism utilizes the rhizosphere colonization and signaling molecule-mediated effects of Bacillus subtilis to enhance crop stress resistance and soil microecological regulation.

Benefits of technology

It enhances crop low-temperature tolerance, promotes growth, improves soil microecology, increases crop yield, and is environmentally friendly, suitable for a variety of crops and greenhouse cultivation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of agricultural biotechnology and discloses a low-temperature synergistic biological agent, its preparation method, and its application. The core innovation lies in using a unique engineered Bacillus subtilis strain as the core functional carrier, and performing a ternary targeted compounding with polydeoxyribonucleotides (PDRN) and biostimulants to achieve a triple synergistic low-temperature resistance effect. The engineered Bacillus subtilis strain was deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 11, 2026, with accession number CGMCC No. 37899. The chassis strain of Bacillus subtilis was deposited at the same center on March 3, 2026, with accession number CGMCC No. 37834. The modification strategy involves knocking out the α-subunit gene of acetoin dehydrogenase and the phosphoacetyltransferase gene from the genome of Bacillus subtilis CGMCC No. 37834, and expressing the acetyllactate synthase gene and the α-acetyllactate decarboxylase gene.
Need to check novelty before this filing date? Find Prior Art